4 Indian pharma stocks eyeing the biggest opportunity since generics

Indian pharmaceutical companies are shifting focus from generic medicines to biosimilars to capture a massive global market. As blockbuster drugs like Keytruda lose patent protection, firms are investing in complex manufacturing. Biocon leads this transition, as biosimilars already contribute 60% of its business, showing the industry’s next big growth phase.